Therapeutic Immunization for Recurrent Herpes Simplex Virus Infections

McKenzie, Robin; Straus, Stephen E.

doi:10.1007/978-1-4757-9209-6_9

Cited by 7 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous approaches to developing an effective vaccine against HSV-2 have been investigated, including killed whole virus, DNA-free virus preparations, and specific viral subunits [8][9][10][11][12]. Although the results of rodent protection experiments and early human clinical trials with several vaccines were encouraging, the results from placebo-controlled human trials did not meet the recommended standards for an HSV vaccine [13].…”

mentioning

confidence: 99%

Plasmid DNA–Expressed Secreted and Nonsecreted Forms of Herpes Simplex Virus Glycoprotein D2 Induce Different Types of Immune Responses

Higgins

Herold²,

Arnold

et al. 2000

J INFECT DIS

View full text Add to dashboard Cite

Herpes simplex viruses (HSVs) are significant pathogens and major targets of vaccine development. Several attempts have been made to develop prophylactic and therapeutic vaccines for HSV types 1 and 2. Although these vaccines elicit strong humoral responses, the overall impact on pathology has been disappointing. An effective vaccine for HSV must induce both humoral and cellular immune responses. DNA vaccines are ideal candidates for HSV vaccines because they induce both types of immune responses. This study showed that the type of immune response generated by immunization with DNA vaccines is modulated by expression of various forms of an antigen, each with a different cellular localization. Expression of cell-associated forms of HSV-2 glycoprotein D (gD) induces primarily a Th1 response, whereas expression of secreted gD results in a Th2 response. Immunization with plasmids expressing different forms of the antigen may increase the efficacy of a vaccine.

show abstract

mentioning

confidence: 99%